v3.26.1
Condensed Statement of Changes in Shareholders’ Deficit (Unaudited) - 3 months ended Mar. 31, 2026 - USD ($)
Ordinary Shares
Class A
Ordinary Shares
Class B
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2025 $ 767 $ 24,233 $ (99,715) $ (74,715)
Balance (in shares) at Dec. 31, 2025 7,666,667 [1]      
Accretion of Class A ordinary shares to redemption amount (9,374,554) (7,168,477) 16,543,031
Sale of private placement units $ 70 6,949,930 6,950,000
Sale of private placement units (in shares) 695,000 [1]      
Fair Value of Public Warrants at issuance 2,568,333 2,568,333
Allocated value of transaction costs to Class A ordinary shares (167,942) (167,942)
Net income 546,079 546,079
Balance at Mar. 31, 2026 $ 767 $ (6,722,113) $ (6,721,276)
Balance (in shares) at Mar. 31, 2026 7,666,667 [1]      
[1] Includes up to 1,000,000 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. In December 2025, the Company issued additional 1,916,667 founder shares through a share capitalization resulting in the Sponsor holding 7,666,667 founder shares in the aggregate. All share and per-share data have been retrospectively presented (see Note 5 and Note 7). On February 20, 2026, the underwriters exercised their over-allotment option in full to be settled as part of the closing of the Initial Public Offering. As a result of the underwriters’ election to fully exercise their over-allotment option, 1,000,000 founder shares are no longer subject to forfeiture by the Sponsor (see Note 7).